Kornitzer Capital Management Inc. KS increased its stake in Illumina Inc. (NASDAQ:ILMN) by 6.1% during the second quarter, Holdings Channel reports. The fund owned 42,202 shares of the life sciences company’s stock after buying an additional 2,430 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Illumina were worth $5,924,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Rockefeller Financial Services Inc. raised its stake in Illumina by 11,812.5% in the second quarter. Rockefeller Financial Services Inc. now owns 271,962 shares of the life sciences company’s stock valued at $38,177,000 after buying an additional 269,679 shares in the last quarter. Temasek Holdings Private Ltd raised its stake in Illumina by 163.2% in the first quarter. Temasek Holdings Private Ltd now owns 277,261 shares of the life sciences company’s stock valued at $44,947,000 after buying an additional 171,900 shares in the last quarter. Bellevue Group AG acquired a new stake in Illumina during the first quarter valued at approximately $14,853,000. PGGM Investments raised its stake in Illumina by 299.6% in the second quarter. PGGM Investments now owns 94,364 shares of the life sciences company’s stock valued at $13,247,000 after buying an additional 70,749 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in Illumina by 2,610.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 51,500 shares of the life sciences company’s stock valued at $8,349,000 after buying an additional 49,600 shares in the last quarter. Institutional investors own 95.24% of the company’s stock.
Illumina Inc. (NASDAQ:ILMN) traded up 2.34% during midday trading on Monday, hitting $141.23. The company had a trading volume of 1,444,699 shares. The company has a market cap of $20.70 billion, a P/E ratio of 48.37 and a beta of 0.47. The company’s 50 day moving average is $171.14 and its 200-day moving average is $156.05. Illumina Inc. has a one year low of $127.10 and a one year high of $196.47.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.13. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The business had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. During the same period last year, the business earned $0.80 EPS. The firm’s revenue was up 11.3% compared to the same quarter last year. On average, equities analysts predict that Illumina Inc. will post $3.53 EPS for the current year.
ILMN has been the topic of several recent research reports. Morgan Stanley lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and decreased their price objective for the stock from $130.00 to $110.00 in a research report on Tuesday, July 5th. Vetr raised shares of Illumina from a “sell” rating to a “buy” rating and set a $198.61 target price for the company in a research note on Monday, October 3rd. CL King downgraded shares of Illumina from a “buy” rating to a “neutral” rating in a research note on Monday, August 22nd. Cantor Fitzgerald cut their target price on shares of Illumina from $165.00 to $155.00 and set a “hold” rating for the company in a research note on Tuesday, October 11th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Illumina from $185.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 27th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $156.88.
In other Illumina news, Director Robert S. Epstein sold 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $150.00, for a total value of $180,000.00. Following the sale, the director now owns 7,824 shares of the company’s stock, valued at approximately $1,173,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $172.99, for a total value of $3,459,800.00. Following the completion of the sale, the director now directly owns 508,061 shares in the company, valued at approximately $87,889,472.39. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.